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Systematic engineering of artificial metalloenzymes 
for new-to-nature reactions
Tobias Vornholt1,2, Fadri Christoffel2,3*, Michela M. Pellizzoni2,3*†, Sven Panke1,2,  
Thomas R. Ward2,3, Markus Jeschek1,2‡
Artificial metalloenzymes (ArMs) catalyzing new-to-nature reactions could play an important role in transitioning 
toward a sustainable economy. While ArMs have been created for various transformations, attempts at their 
genetic optimization have been case specific and resulted mostly in modest improvements. To realize their full 
potential, methods to rapidly discover active ArM variants for ideally any reaction of interest are required. 
Here, we introduce a reaction-independent, automation-compatible platform, which relies on periplasmic com-
partmentalization in Escherichia coli to rapidly and reliably engineer ArMs based on the biotin-streptavidin tech-
nology. We systematically assess 400 ArM mutants for five bioorthogonal transformations involving different 
metals, reaction mechanisms, and reactants, which include novel ArMs for gold-catalyzed hydroamination and 
hydroarylation. Activity enhancements up to 15-fold highlight the potential of the systematic approach. 
Furthermore, we suggest smart screening strategies and build machine learning models that accurately predict 
ArM activity from sequence, which has crucial implications for future ArM development.
INTRODUCTION
Artificial metalloenzymes (ArMs) combine the broad reaction scope 
of organometallic catalysis with the exceptional catalytic perform­
ance, selectivity, and mild reaction conditions of enzymes (1, 2). 
Therefore, they have a great potential to enable sustainable synthetic 
routes to various compounds of interest (3, 4) and, if functional in a 
cellular environment, open up new possibilities for metabolic engi­
neering and synthetic biology (5). ArMs have been constructed by 
repurposing natural metalloenzymes (6, 7), designing binding sites 
for metal ions (8–11), and incorporating organometallic cofactors 
into protein scaffolds (12–20). Moreover, unnatural amino acids 
(21) and photoexcitation (22, 23) have been used to unlock new 
reactivity in enzymes. Among these efforts to create new­to­nature 
biocatalysts, one of the most versatile approaches relies on the 
biotin­streptavidin technology. This strategy uses the high affinity of 
the homotetrameric protein streptavidin (Sav) for the vitamin d­biotin 
to noncovalently anchor biotinylated metal complexes (referred to 
as cofactor hereafter) within the Sav protein. Using this approach, 
artificial enzymes have been created for multiple reactions, including 
hydrogenation, sulfoxidation, C─H activation, and olefin metathe­
sis (24–26). While in some cases wild­type Sav imparts some selectivity 
or rate acceleration on the reaction, protein engineering is usually 
required to obtain proficient biocatalysts (27–31). Initial studies in 
this direction relied on screening (semi­)purified Sav mutants (32, 33), 
but more recently, a trend toward whole­cell screening with 
Escherichia coli has emerged for Sav­based ArMs (34, 35) and other 
artificial enzymes (8, 36, 37). This allows substantially increased 
throughput and is the method of choice if variants that are functional 
under in vivo conditions are desired, which is an important pre­
requisite for synthetic biology applications.
However, a number of challenges arise for cell­based ArM assays, 
most notably insufficient cofactor uptake into the cell and cofactor 
poisoning by cellular components such as reduced glutathione (38). 
To circumvent these challenges, Sav has been exported to the peri­
plasmic space (34) or the cell surface (35). While these studies have 
established the possibility of engineering ArMs using whole­cell 
screenings, they did so using case­specific engineering strategies and 
with a focus on reactions affording fluorescent products. Conse­
quently, applicability of these methods across a wider range of reac­
tions remains to be demonstrated. To generalize the development 
of ArMs, broadly applicable engineering strategies that enable the 
rapid identification of highly active variants for ideally any reaction 
of interest are needed. This requires a robust screening protocol that 
is compatible with various reaction conditions and analytical read­
outs. Moreover, it imposes a demand for Sav mutant libraries that 
embody a high potential to contain highly active variants for different 
reactions while maintaining a comparably small and thus screenable 
library size. Such a combination of a versatile, reaction­independent 
screening method with a “concise” library could serve as a universal 
starting point for various ArM engineering campaigns and would render 
tedious case­by­case method and library development obsolete. Here, 
we present a screening platform that meets the aforementioned require­
ments as a first systematic approach to ArM engineering. We establish 
a well plate–based screening protocol that can be easily adapted to new 
reaction conditions or analytical methods and show that it is amenable 
to lab automation as an important prerequisite for streamlined ArM 
engineering. Furthermore, we create a full­factorial, sequence­defined 
Sav library that is rich in variants with high activity by simultaneously 
diversifying two crucial amino acid positions in close vicinity to the 
catalytic metal. To demonstrate the versatility of this platform, we 
selected five bioorthogonal reactions requiring different cofactors, 
reaction conditions, and analytical readouts. The platform enabled the 
identification of substantially improved ArMs for all tested reactions 
with fast turnaround times. Moreover, the systematic characterization 
of the local sequence­activity landscape enabled us to identify smart 
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library designs to further enhance the development of ArMs and to 
construct machine learning models that predict the activity of ArMs 
with high precision. This study represents the first systematic ap­
proach to ArM engineering and thus constitutes an important step 
toward a streamlined optimization of these promising biocatalysts.
RESULTS
Construction and characterization of a sequence-defined 
Sav library
To establish a generalizable first engineering step for ArMs, we sought 
to generate a library of Sav variants that offers a high likelihood of 
identifying active variants at a minimized screening effort. On the 
basis of previous experience with Sav expression and whole­cell ArM 
catalysis (34, 35), we selected a periplasmic compartmentalization 
strategy for this library. Secretion to the periplasm and subsequent 
ArM assembly represent a good trade­off between accessibility to 
the cofactor, expression levels, and compatibility of the reaction 
conditions (39). To facilitate periplasmic export in E. coli, the signal 
peptide of the outer membrane protein A (OmpA) was N­terminally 
fused to T7­tagged mature Sav (referred to as wild type hereafter) as 
previously reported (34). The holoenzyme (i.e., full ArM with co­
factor) can then be assembled in the periplasm by incubating cells 
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Fig. 1. Systematic screening of ArMs. (A) Sav is secreted to the periplasm, where it binds an externally added biotinylated cofactor, which consists of a catalytic metal 
M and ligands L and L′, to afford an ArM. OmpA, periplasmic export signal from outer membrane protein A. (B) Left: Biotinylated metathesis cofactor embedded in the 
biotin-binding vestibule of homotetrameric Sav (Protein Data Bank 5IRA). Symmetry-related residues S112/S′112 (blue) and K121/K′121 (purple) are in the immediate vicinity 
of the cofactor and were mutated (right) to afford an Sav library of 400 amino acid combinations. (C) Expression level of periplasmic Sav mutants as determined in cell lysate 
using a fluorescence quenching assay (Methods) (41). Means of biological triplicates (n = 3) normalized to the OD600 of the cultures are displayed (see fig. S4 for SD). (D) Esti-
mated percentage of Sav mutants with unoccupied biotin-binding sites as a function of the cofactor concentration added to the cell suspension (assuming 50% uptake 
into the periplasm). Ten micromolars was selected as maximum-permitted cofactor concentration for further experiments to ensure an excess of binding sites for >90% 
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selected the amino acid residues 112 and 121 in Sav as randomiza­
tion targets, which correspond to serine and lysine in wild­type Sav. 
These residues are in close proximity to the biotinylated cofactor 
(32) (Fig. 1B) and have repeatedly been found to have a substantial 
impact on the activity of ArMs for diverse cofactors and reactions 
(33–35). More specifically, we created a combinatorial Sav 112X 
121X library (X representing all 20 canonical amino acids) consisting 
of all 400 possible amino acid combinations for these two positions. 
Such a full­factorial library makes it possible to identify improved 
mutants that are the result of synergistic interactions between the two 
positions. We applied a three­step cloning and sequencing strategy 
(see Methods and figs. S1 to S3) to produce an arrayed, sequence­ 
verified set of all 400 possible Sav 112X 121X mutants. This minimizes 
the screening effort by avoiding the requirement for oversampling.
Even single mutations can substantially alter the expression level 
of proteins (40), which complicates the identification of variants with 
increased specific activity. For this reason, we aimed to screen at 
cofactor concentrations that do not fully saturate the available biotin­ 
binding sites even for low­expressing variants (i.e., excess of binding 
sites). Consequently, we determined the expression level of all 400 Sav 
mutants from the 112X 121X library, relying on a quenching assay 
with biotinylated fluorescent probes (Fig. 1C and Methods) (41). 
The majority of variants showed high expression levels ranging from 
17 to 536 mg liter−1, which is equivalent to concentrations of 1 to 33 M 
biotin­binding sites. When normalized by the density of the cell 
suspensions, these values amount to 0.2 to 3.2 M binding sites in a 
culture with an optical density at 600 nm (OD600) of 1. While the 
expression of variants harboring a cysteine at position 112 or a tryp­
tophan at either of the two positions appeared to be reduced, 87% of 
Sav mutants showed an expression level greater than 1 M binding 
sites per OD600. On the basis of these measurements, we determined 
a maximum permitted cofactor concentration (Fig. 1D). This critical 
experimental parameter should, on the one hand, be high enough to 
result in well­detectable product concentrations and, on the other 
hand, remain below the concentration of available biotin­binding 
sites for the majority of the library. The latter requirement is important 
to keep the concentration of assembled ArMs constant, irrespective 
of the expression level of Sav. In light of previous studies (34) and 
our own observations (fig. S5), we conservatively assumed that less 
than half of externally added cofactor enters the periplasm. As a conse­
quence, we set the maximum permitted cofactor concentration at 
the incubation step to 10 M, because this ensures that an excess of 
binding sites is maintained for more than 90% of variants (Fig. 1D), 
thus largely eliminating the expression level dependence of the 
screening results.
Systematic screening of ArMs for bioorthogonal reactions
To facilitate screening of improved ArMs for diverse reactions, we 
relied on a 96­well plate–based assay (34). In brief, periplasmic ex­
pression cultures are spun down, and cells are resuspended in an 
incubation buffer containing the cofactor of interest to assemble the 
ArM in the periplasm. After incubation, cells are washed once to 
remove unbound cofactor and resuspended in a reaction­specific 
buffer containing the substrate. Following overnight incubation, the 
product concentration is determined using a suitable analytical 
method (Fig. 1E). This screening procedure is compatible with var­
ious reaction conditions and analytical methods and, consequently, 
not restricted to model reactions, which, for example, produce a 
fluorescent product. Furthermore, it is amenable to lab automation 
(see below). Relying on this protocol, we sought to systematically 
test the full­factorial 400­mutant Sav library for various ArM reac­
tions of interest (Fig. 2A). To this end, we selected three reactions 
based on previously reported ArMs: a ring­closing metathesis (RCM, I) 
of diallyl­sulfonamide 1 to 2,5­dihydro­pyrrole 2 (34) and two deallyl­
ation reactions (II and III) of allyl carbamate–protected substrates 
3 and 5, affording amino coumarin 4 and indole 6, respectively. The 
corresponding cofactors for these reactions are a biotinylated second­ 
generation Hoveyda­Grubbs catalyst (Biot-NHC)Ru (reaction I) 
and a biotinylated ruthenium cyclopentadienyl complex (Biot-HQ)
CpRu (42, 43) (reactions II and III), respectively (Fig. 2B). Furthermore, 
with the aim of extending the scope of ArM­catalyzed reactions toward 
biocompatible nucleophilic cyclizations of alkynes, we developed 
two novel gold­containing ArM cofactors, (Biot-NHC)Au1 and 
(Biot-NHC′)Au2 (Fig. 2B), to create ArMs for hydroamination 
(IV) and hydroarylation (44) (V) reactions. None of these reactions 
are known to be catalyzed by natural enzymes, and therefore, they 
have potential for applications ranging from the design of novel meta­
bolic pathways to prodrug activation and in vivo labeling (5, 45).
While preliminary experiments on the RCM I and deallylations 
II and III confirmed the compatibility of these reactions with the 
periplasmic screening platform, reactions IV and V showed only 
little conversion in the whole­cell assay. On the basis of previous 
experience with ArMs (34, 38), we hypothesized that cellular thiols 
might inhibit these gold­catalyzed reactions, which we could con­
firm by in vitro experiments with purified Sav. These revealed a marked 
inhibitory effect of glutathione and cysteine (fig. S6A). Previously, 
we had reported that thiol inhibition can be overcome in vitro by 
adding the oxidizing agent diamide (38). We observed that diamide 
also neutralizes the detrimental effect of thiols in whole­cell experi­
ments, rendering periplasmic gold catalysis feasible (fig. S6B).
With a functional periplasmic screening assay for the five reac­
tions at hand, we tested all 400 mutants for each reaction at least in 
biological duplicates relying on the aforementioned workflow in 
96–deep well plates. We automated the steps required for incuba­
tion with cofactor, washing, and substrate addition and applied this 
automated protocol for reactions II and V. This substantially reduces 
the manual labor and the consumption of consumables. The robotic 
platform can handle up to eight 96­well plates concurrently. Accord­
ingly, the 400­member library can be processed in 1 day, and an entire 
screening (including Sav expression and analytics) can be performed 
within 1 week.
Relying on the periplasmic assay, we recorded a local sequence­ 
activity landscape for each ArM (Fig. 2C). The activity patterns varied 
substantially between reactions, which points to the existence of 
specific interactions between protein, cofactor, and substrate, as 
opposed to unspecific effects, for instance, as a result of varying 
expression levels. In line with this, we observed no correlation be­
tween expression level and activity for any of the reactions (fig. S7). 
Hence, the concentration of cofactor, and not the number of avail­
able biotin­binding sites, is limiting, which confirms the validity of 
the determined maximum cofactor concentration (see above). Similar 
activity patterns were only found between the two deallylation reac­
tions (II and III), suggesting that, in these cases, the substrates are 
sufficiently similar or that the observed activity is mainly the result 
of interactions between protein and cofactor.
For all reactions, the wild­type variant (S112 K121) had a com­
parably low activity that was only slightly above the background 
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Fig. 2. Systematic screening for ArMs catalyzing diverse reactions. (A) ArM-catalyzed reactions: I, ring-closing metathesis (RCM) with a diallyl-sulfonamide 1 yielding 
a 2,5-dihydro-pyrrole 2. II, Deallylation of allylcarbamate-protected coumarin 3 to the corresponding amino coumarin 4. III, Deallylation of allyl carbamate indole 5 to 
indole 6. IV, Hydroamination of 2-ethynylaniline 7 to indole 6. V, Hydroarylation of profluorophore 8 to afford amino coumarin 9. (B) Biotinylated cofactors used in this 
study. Biot: d-biotin. (C) Cell-specific activity of 400 ArMs mutated at Sav positions 112 and 121 normalized to the activity of wild-type Sav (S112 K121). The displayed ac-
tivities are product concentrations after 20 hours of reaction (mean of biological duplicates; for SDs, refer to fig. S8). Note that the screenings for reactions II and V were 
performed using robotics. (D) Activity distribution in the Sav mutant library for the five ArM reactions. Violins comprise 400 double mutants with the 10 most active ArMs 
depicted as circles. (E) Validation of hits from the 400 mutant screens. Bars are mean activity of eight biological replicates with SD (error bars) and individual replicates 
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results from residual cofactor that is unspecifically bound and thus 
incompletely removed in the washing step. Compared with wild­
type Sav, we identified significantly more active mutants for all five 
ArM reactions (Fig. 2D). To validate these results, we measured the 
activity of the most promising variants of each ArM again in eight 
replicates, which confirmed the observed enhancements (Fig. 2E). 
The best mutants reached fold improvements over the wild type 
varying between 6­ and 15­fold. Notably, we also identified sub­
stantially improved variants of the novel, gold­based ArMs for 
hydroamination (IV) and hydroarylation (V), reaching fold improve­
ments over wild type of about 7­ and 10­fold, respectively.
While the screenings were designed toward increased ArM ac­
tivity in a cellular environment, we sought to investigate whether the 
identified variants also display increased activity in vitro. We there­
fore purified the three most active mutants for each reaction and 
performed ArM reactions with these (Fig. 3). Notably, all mutants 
significantly outperformed the wild­type ArM and the correspond­
ing free cofactor, as reflected by markedly higher turnover numbers 
(TONs). Depending on the reaction, the best variants reached between 
5­ and 20­fold higher TONs than the free cofactor, demonstrating 
the benefit of embedding these cofactors within an engineered pro­
tein scaffold. Note that, in some cases, the relative ranking of vari­
ants changed compared with the whole­cell biotransformations, which 
is likely due to the different reaction conditions and the absence of 
cellular components in vitro. Nevertheless, the in vitro experiments 
confirmed that the identified variants have a significantly increased 
specific activity and further corroborated the potential of the peri­
plasmic screening platform for the rapid and straightforward dis­
covery of different ArMs with improved catalytic properties.
Analysis of sequence-activity landscapes
The recording of sequence­activity data as performed here provides 
the basis for additional insight beyond the mere identification of 
active mutants. To this end, we first sought to understand which 
biophysical properties result in the observed activity changes. There­
fore, we analyzed the effect of individual amino acids on the activity 
of the different ArMs (Fig. 4A): First, we scaled the activity mea­
surements (Fig. 2C) such that the average activity across the 400 
mutant library equals zero and the corresponding SD equals 1. 
Next, we averaged the scaled activities of all 20 variants that carry 
the same amino acid in one position. This was performed for all 
20 canonical amino acids and either of the two diversified positions. 
As a result, amino acid– and position­specific averages greater or 
smaller than zero represent a positive or negative effect on ArM 
catalysis, respectively. While effects of amino acids varied between 
positions and reactions (Fig. 4A), an overall positive effect of hydro­
phobic amino acids on the activity of the corresponding ArMs could 
be observed, whereas charged amino acids and proline tend toward 
a negative impact. In addition, we used hierarchical clustering to ana­
lyze which amino acids have similar effects on activity. In line with 
the previous observation, hydrophobic amino acids clustered clearly 
separated from hydrophilic ones, indicating that this property is 
crucial in terms of catalytic activity (Fig. 4B). Furthermore, amino 
acids with similar chemical properties showed a strong tendency 
to cluster closely together (note, for instance, L­I­V, D­E, H­K, 
and S­T clusters). This points to an anticipated large potential 
of library strategies that use reduced amino acid alphabets to maintain 
a large chemical diversity while significantly reducing the screening 
effort (see below).
Next, we compared the full­factorial screening approach as 
pursued here with other common enzyme engineering strategies. 
To this end, we used our screening results to analyze which variants 
would have been identified using such heuristics, and how their 
activity compares to the most active variant identified in our ex­
haustive screening. As highlighted in Figure 4C, screening only single 
mutants (S112X K121 or S112 K121X) would have led to “hits” with 
activities ranging from 26 to 65% relative to the most active double 
mutant for the respective ArM reaction. Subsequent combination 
of the most beneficial single mutations would have led to an activity 
increase in two cases but a decrease in three cases. This suggests that 
there are interactions between the two amino acid positions 112 and 
121 that lead to nonadditive effects on the overall activity (46). Further 
analysis revealed that between 24 and 37% of the observed variance 
can be attributed to interactions between the two positions (table S1). 
Notably, the activity of the best mutants identified in our screening 
can only be explained by considering nonadditive effects (fig. S9).
Iterative saturation mutagenesis (ISM) relies on the sequential 
randomization of positions while using the best variant from the 
previous round as a starting point for the next (47). In this way, it 
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Fig. 3. In vitro turnover number of ArM variants identified in the periplasmic 
screening. For each reaction, the three most active variants identified in the whole- 
cell screening were purified, and their TON was determined. Reactions were carried 
out at 37°C and 200 rpm for 20 hours. Bars represent mean TONs of technical tripli-
cate reactions with SD as error bars and individual replicates as circles. For comparison, 
the free cofactor and wild-type Sav variant (wt) were included. Mutants are designated 
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Fig. 4. Amino acid effects and implications for future ArM engineering. (A) Effect of amino acids on ArM activity. Points outside and inside the dark gray circles indi-
cate a positive and negative effect, respectively. Values were standardized by subtracting the mean activity of all 400 mutants and dividing by the corresponding SD. The 
mean across all 20 variants harboring the respective amino acid is shown. (B) Hierarchical clustering of amino acids across both positions and all reactions (Methods). 
NDT-encoded amino acids are highlighted (blue). (C) Comparison of enzyme engineering strategies. Strategies are compared to the full-factorial approach (left to right): 
screening single mutants (both positions), combining the best single mutations at both positions, ISM, and combinatorial screening with reduced amino acid sets (NDT/
NRT codons). Bars are the mean across hits identified by the respective strategy. (D) Predictive machine learning models based on SVM, gradient boosting, and neural 
networks (Methods). Models were trained on 320 randomly selected data points and evaluated on the remaining 80 variants. Mean and SD of five training runs are dis-
played for gradient boosting and neural networks. (E) Performance of gradient boosting model for reaction III. Predictions are plotted against experimental measure-
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can leverage nonadditive interactions to some extent while keeping 
the experimental effort limited. This strategy would have been more 
successful than the simple combination of single mutations and would 
have led to the discovery of mutants at or near the local activity 
optimum for two of the five reactions. Nonetheless, this demonstrates that 
a full­factorial library enables the discovery of mutants that would likely 
be missed using other strategies, as they are the result of nontrivial 
interactions. In addition, note that while sequential strategies require the 
analysis of fewer variants, they do not provide universally applicable 
libraries, which would be a substantial disadvantage for a generalizable, 
reaction­independent ArM screening platform as proposed here.
Unfortunately, full­factorial screening quickly becomes intractable 
if more positions are to be diversified. An established strategy to 
decrease library size is to use reduced amino acid sets, such as the 
12 amino acids encoded by NDT “(where N = A, C, G or T and D = 
A, G or T)” codons, which still cover all major classes of amino acid 
chemistries and lack redundant or stop codons (48). Our analysis shows 
that this strategy would have been more successful than those discussed 
above, reaching consistently high activities for all ArM reactions. 
This observation is in line with the fact that these 12 amino acids 
cover the clusters identified in our previous analysis well (Fig. 4B). 
For this reason, it seems promising to screen combinatorial libraries 
of Sav mutants based on such a reduced amino acid set. Further 
reductions in the amino acid set are possible [for example, eight amino 
acids encoded by NRT “(where N = A, C, G or T and R = A or G)’’], 
but at the cost of a reduced probability of finding highly active mutants.
The recording of sequence­activity data as performed here may 
also enable data­driven approaches to ArM engineering that effi­
ciently explore the available sequence space. In recent years, machine 
learning techniques have attracted great interest in the context of 
enzyme engineering, as these could predict the activity of hitherto 
untested enzyme variants directly from their sequence, provided that 
a suitable set of training data is available (49). We therefore assessed 
the utility of different machine learning techniques for the engineering 
of ArMs relying on the sequence­activity data obtained in this study. 
Specifically, we chose three commonly used approaches—support 
vector machine (SVM) regression (50), gradient boosting (51), and 
neural networks (52)—and evaluated their performance for all five 
reactions. After choosing the best sets of hyperparameters using 
fourfold cross­validation, we trained the models on 320 data points 
and evaluated their predictions for the remaining 80 variants (Fig. 4D). 
Overall, predictions correlated well with the experimentally deter­
mined activities (coefficient of determination, R2 between 0.34 and 
0.71). On average, gradient boosting achieved the best predictive 
performance and appeared to be most robust across different reac­
tions (R2 of 0.68, 0.68, 0.71, 0.46, and 0.55 for reactions I, II, III, IV, 
and V, respectively). Last, we selected the best­performing model 
for each reaction to assess whether the predictive power would be 
sufficient to facilitate machine learning–guided ArM engineering. 
We found that the models could be used to design highly active mu­
tants with high confidence (Fig. 4E and fig. S10). This highlights the 
potential of machine learning in the context of ArMs, and similar 
approaches may be used to guide their engineering in the future.
DISCUSSION
The results presented in this study highlight that Sav­based ArMs can 
be tailored to catalyze various new­to­nature reactions. The activity 
landscapes of ArMs are distinct for each reaction, underscoring the 
need for flexible enzyme engineering strategies that can be easily 
adapted to new transformations. The Sav 112X 121X library along 
with the automation­compatible, periplasmic screening workflow 
represent the first platform for systematic ArM engineering to this 
end. Using this approach, we readily identified improved ArMs for 
five biorthogonal reactions. The activity enhancements compare 
favorably to previous efforts of optimizing Sav­based ArMs (34, 35). 
Similarly, the hits appear to be more active than the variants we 
identified previously for the same reactions. For instance, several 
studies had previously described allylic deallylases that uncage 
allylcarbamate­protected substrates. Of these, the most extensive 
engineering study was a screening of 80 surface­displayed variants 
with mutations at positions 112 and 121, yielding the double mu­
tants 112M 121A and 112Y 121S as the most active variants for the 
uncaging of allylcarbamate­protected amino coumarin 3 (II) (35). 
While both of these mutants proved to be highly active in our peri­
plasmic screen, several others displayed even higher activities, reaching 
an improvement over wild type of up to 15­fold, compared with 
9­ and 10­fold for the previously identified variants.
The recorded data on ArM activity and cellular Sav levels indi­
cate that differences in the expression level of Sav mutants do not 
affect the screening performance of our platform, as an excess of 
biotin­binding sites is consistently ensured. This notion is corrobo­
rated by the observation that the best ArM mutants displayed an 
increased specific activity in vitro. At the same time, the large excess 
of binding sites points to a substantial potential to increase the 
cell­specific ArM activity for applications in biocatalysis, which could 
be achieved by increasing the concentration of cofactor and/or im­
proving its uptake.
All reactions tested in the context of this study were found to be 
compatible with whole­cell biotransformations under mild reaction 
conditions, which is an important prerequisite for advanced appli­
cations in the context of synthetic biology (5). In this regard, the 
indole­producing ArMs (reactions III and IV) are of particular in­
terest, as a variety of applications can be imagined on the basis of 
this metabolic intermediate and signaling molecule.
The combinatorial library focused on two crucial residues proved 
to be a powerful tool for the engineering of ArMs, particularly when 
pursuing multiple catalytic activities in parallel from a common 
starting point. The combination of such libraries with the screening 
workflow presented here enables the rapid discovery of active ArMs 
for any new reaction, potentially as a universal initial step followed 
by more extensive engineering campaigns. For the latter, the results 
from this study provide valuable implications such as the indicated 
high potential of reduced amino acid sets in the context of ArMs. 
Combined with lab automation, such amino acid sets render larger 
screening campaigns involving more amino acid positions feasible. 
For much larger numbers of targeted positions in Sav, ISM, poten­
tially in combination with reduced amino acid alphabets, appears to 
be a promising strategy, as it offers a good trade­off between exper­
imental effort and the probability of finding highly active mutants. 
Last, the screening platform could be used to perform undersampling 
of libraries with a much larger theoretical diversity. Subsequently, 
the obtained data may be used to train machine learning models, 
which can guide additional screening rounds and thus streamline 
ArM engineering (49). Our analyses in this regard (Fig. 4, D and E) 
highlight the power of such approaches specifically in the context of 
ArMs. Moreover, our observations indicate that various machine 
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guide the directed evolution of ArMs (53). Note that the datasets 
used for the model training here are relatively small and only allow 
predictions for the two randomized amino acid positions. Nonetheless, 
we anticipate that future screening campaigns with larger libraries 
are likely to profit substantially from such predictive models trained 
on an initial smaller sample of variants.
METHODS
Chemicals and reagents
Unless stated otherwise, chemicals were obtained from Sigma­Aldrich, 
Acros, or Fluorochem. Primers were synthesized by Sigma­Aldrich, 
and enzymes for molecular cloning were obtained from New 
England Biolabs.
Cloning of Sav library
The Sav library was created on the basis of a previously described 
expression plasmid that contains a T7­tagged Sav gene with an 
N­terminal ompA signal peptide for export to the periplasm under 
control of the T7 promoter in a pET30b vector (Addgene, #138589) 
(34). Positions 112 and 121 were randomized using the codon set 
described by Tang et al. (54). The plasmid was amplified in two 
fragments using either primer 1 and a mix of primers 2 to 5 (molar 
ratio of 12:6:1:1) or primer 10 and a mix of primers 6 to 9 (molar 
ratio of 12:6:1:1; see table S2 for primer sequences). Polymerase 
chain reactions (PCRs) were carried out using Q5 polymerase. 
Template plasmid was digested using DpnI, and the PCR products 
were purified using a PCR purification kit (Sigma­Aldrich). Subse­
quently, the fragments were joined by Gibson assembly and used to 
transform chemically competent BL21­Gold(DE3) cells (Agilent 
Technologies). Individual clones were sequence verified by Sanger 
Sequencing (Microsynth AG). Having identified 250 of the 400 possible 
distinct double mutants this way, a second pool containing only the 
150 missing variants was cloned. To this end, sequence­verified 
plasmids from the first library generation step were used as PCR tem­
plates, and 40 fragments, each containing a single amino acid exchange 
at position 112 or 121, were obtained by amplification with primers 
1 and 12 or 10 and 11 for positions 112 and 121, respectively. Fol­
lowing DpnI digest and purification, these fragments were added to 
Gibson assembly reactions in combinations suitable for obtaining pools 
of missing variants. More specifically, this was achieved by adding 
one fragment with a desired mutation at position 112 per reaction, 
along with multiple fragments for position 121. Again, individual clones 
were sequenced after transformation. Eventually, 36 remaining variants 
were cloned individually by assembling the corresponding fragments. 
Refer to fig. S1 for an overview of the library generation.
Sav expression in 96-well plates
Ninety­six deep­well plates were filled with 500 l of LB (+ 50 mg 
liter−1 kanamycin) per well. Cultures were inoculated from glycerol 
stocks and grown overnight at 37°C and 300 revolutions per minute 
(rpm) in a Kuhner LT­X shaker (50­mm shaking diameter). Twenty 
microliters per culture was used to inoculate expression cultures in 
1 ml of LB with kanamycin. These cultures were grown at 37°C and 
300 rpm for 1.5 hours. At this point, the plates were placed at room 
temperature for 20 min, and subsequently, Sav expression was in­
duced by addition of 50 M isopropyl ­d­1­thiogalactopyranoside 
(IPTG). Expression was carried out at 20°C and 300 rpm for an 
additional 20 hours.
Quantification of biotin-binding sites
For measurement of Sav expression levels, the OD600 of the cultures 
was determined in a plate reader (Infinite M1000 PRO, Tecan 
Group AG) using 50 l of samples diluted with an equal volume of 
phosphate­buffered saline (PBS). The remaining cultures were then 
centrifuged [3220 relative centrifugal force (rcf), 20°C, 10 min], and 
the pellets were resuspended in 250 l of lysis buffer [50 mM tris, 
150 mM NaCl, 5 mM EDTA, and 1 g  liter−1 lysozyme (pH 7.4)]. 
After 30 min of incubation at room temperature, the cell suspen­
sions were subjected to three freeze­thaw cycles. Afterward, 150 l 
of deoxyribonuclease I (DNaseI) buffer [50 mM tris, 150 mM NaCl, 
and 2 U ml−1 DNaseI (pH 7.4)] was added, and plates were incubat­
ed at 37°C for 45 min before centrifugation (4800 rcf, 20°C, 20 min). 
Subsequently, the concentration of biotin­binding sites in the 
supernatant was determined using a modified version of the assay 
described by Kada et al. (41), which relies on the quenching of the 
fluorescence of a biotinylated fluorophore upon binding to Sav. 
Specifically, 190 l of the binding site buffer [1 M biotin­4­fluorescein, 
bovine serum albumin (0.1 g liter−1) in PBS] was mixed with 10 l 
of supernatant or purified Sav standard. After incubation at room 
temperature for 90 min, the fluorescence intensity was measured 
(excitation at 485 nm, emission at 525 nm), and a calibration curve 
produced with purified Sav was used to calculate the concentration 
of biotin­binding sites in each sample.
Synthesis of cofactors and substrates
Substrates 1 (34), 3 (35), 5 (55), and cofactors (Biot-NHC)Ru (56) 
and (Biot-HQ)CpRu (35) were prepared according to reported 
procedures. Substrate 7 was obtained from Sigma­Aldrich. A detailed 
description of the synthesis of (Biot-NHC)Au1, (Biot-NHC′)Au2, 
substrate 8, and product 9 is available in the Supplementary Materials.
Whole-cell screening
Following the expression of Sav mutants in deep­well plates, the 
OD600 of the cultures was determined in a plate reader using 50 l of 
samples diluted with an equal volume of PBS. Afterward, the plates 
were centrifuged (3220 rcf, 15°C, 10 min), the supernatant was dis­
carded, and the pellets were resuspended in 400 l of incubation 
buffer containing the respective reaction­specific cofactor. The 
composition of the incubation buffer varied for metathesis [2 M 
(Biot-NHC)Ru in 50 mM tris, 0.9% (w/v) NaCl (pH 7.4)], deallyla­
tion [5 M (Biot-HQ)CpRu in 50 mM MES, 0.9% NaCl (pH 6.1)], 
hydroamination [10 M (Biot-NHC)Au1 in (2­(N­morpholino)
ethanesulfonic acid) 50 mM MES, 0.9% NaCl, 5 mM diamide (pH 6.1)], 
and hydroarylation [10 M (Biot-NHC′)Au2 in 50 mM MES, 0.9% 
NaCl, 5 mM diamide (pH 5)] reactions. The compositions of dif­
ferent buffers are summarized in table S3. Cells were incubated with 
the cofactor for 1 hour at 15°C and 300 rpm. Afterward, plates were 
centrifuged (2000 rcf, 15°C, 10 min), the supernatant was discarded, 
and the pellets were resuspended in 500 l of the respective incuba­
tion buffer lacking cofactor to remove unbound cofactor. Following 
another centrifugation step, cell pellets were resuspended in 200 l 
of reaction buffer containing the respective substrate. The composi­
tion of this reaction buffer varied for metathesis [5 mM 1 in 100 mM 
sodium acetate, 0.5 M MgCl2 (pH 4)], deallylation [500 M 3 or 5 in 
50 mM MES, 0.9% NaCl (pH 6.1)], hydroamination [5 mM 7 in 50 mM 
MES, 0.9% NaCl, 5 mM diamide (pH 6.1)], and hydroarylation [5 mM 
9 in 50 mM MES, 0.9% NaCl, 5 mM diamide (pH 5)] reactions (table S3). 
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determining the product concentration. Each 96­well plate contained 
80 mutants to be tested along with four replicates of cells expressing 
wild­type Sav, Sav SL, Sav MA, and cells lacking Sav as controls. To 
account for differences in cell density and plate­to­plate variations, the 
product concentrations were divided by the OD600 of the culture and 
normalized to the mean of the cell­specific product concentrations 
measured for the Sav SL (metathesis, hydroamination, and hydro­
arylation) or Sav MA (deallylation) controls on the respective plate. 
These mutants had been identified as active in preliminary experi­
ments. All variants were tested at least in biological duplicates.
Lab automation
The steps required for incubation of cells with cofactor, washing, 
substrate addition, and OD600 measurement were implemented using 
an automation platform featuring two Tecan EVO 200 (Tecan 
Group AG) robotic platforms coupled to each other. Both platforms 
were controlled using the EVOware standard software (Tecan 
Group AG). For shaking, incubation, and resuspension of cultures, 
the platform was equipped with Kuhner ES­X shaking platform 
(Adolf Kühner AG) running at 300 rpm at 50­mm shaking radius. 
The shaking platform was surrounded by a custom­made box made 
of aluminum plastic composite panels (Tecan Group AG). The tem­
perature inside the box was maintained at 15°C using an “Icecube” 
(Life imaging services) heater/cooler device. Centrifugation of the 
samples was performed using the integrated Rotanta 46 RSC Robotic 
centrifuge (Hettich AG). All buffer exchanges during sample prepa­
ration were performed using the integrated liquid­displacement 
pipetting system equipped with eight 2500­l dilutors and fixed 
stainless steel needles. OD600 measurements were performed using 
a Tecan Infinite M200 PRO plate reader. The automation method 
files are available upon request. The automated protocol was used 
for the deallylation with allyl carbamate coumarin (II) and the 
gold­catalyzed hydroarylation (V), while the screenings for the oth­
er reactions were performed manually.
Product quantification by ultraperformance liquid 
chromatography–mass spectrometry
To quantify the metathesis product 2, an extraction was performed 
by adding 775 l of methanol and 25 l of internal standard (100 M 
in methanol) to each 200­l sample. The samples were incubated 
for 1 hour at 20°C and 300 rpm, followed by centrifugation at 3220 rcf 
and 20°C for 10 min. Subsequently, 50 l of the supernatant was 
mixed with 200 l of water and analyzed by ultraperformance liquid 
chromatography–mass spectrometry (UPLC­MS). UPLC analysis 
was performed using a Waters H­Class Bio using a BEH C18 1.7­M 
column and a flow rate of 0.6 ml min−1 (eluent A, 0.1% formic acid 
in water; eluent B, 0.1% formic acid in acetonitrile; gradient at 
0 min: 90% A, 10% B; at 0.5 min: 90% A, 10% B; at 2.5 min: 10% A, 
90% B; at 3.5 min: 90% A, 10% B; and at 4.5 min: 90% A, 10% B). 
Peak integration for single ion recording was used for quantification, 
and concentrations of the metathesis product (retention time of 
1.0  ± 0.25 min) were determined on the basis of a standard curve 
with the ring­closed product in the presence of a fixed concentra­
tion of the nonadeuteraded product (retention time of 1.0 ± 0.25 min).
Fluorescence measurements
The fluorescent product 4 was quantified by measuring the fluores­
cence intensity at an excitation of 394 nm and an emission of 
460 nm. Product 9 was excited at 390 nm and measured at 488 nm. 
Measurements were carried out in black 96­well plates in an Infinite 
M1000 PRO plate reader.
Kovac’s assay
Indole was quantified using the photometric Kovac’s assay [adapted 
from Piñero­Fernandez et al. (57)]. For measurements in culture 
supernatant, plates were centrifuged (3220 rcf, 20°C, 10 min), and 
110 l of supernatant was mixed with 165 l of Kovac’s reagent 
[4­(dimethylamino)benzaldehyde (50 g liter−1), isoamylic alcohol 
(710 g liter−1), and hydrochloric acid (240 g liter−1)] in a separate plate. 
After 5 min of incubation, these plates were centrifuged (3220 rcf, 
20°C, 10 min). Subsequently, 75 l of the upper phase was trans­
ferred to a new transparent plate, and the absorbance at 540 nm was 
measured in a plate reader (Infinite M1000 PRO). The same proce­
dure (omitting the first centrifugation step) was applied to measure 
indole after in vitro experiments. A standard curve was then used to 
determine indole concentrations.
Sav expression for purification
A single colony of BL21­Gold(DE3) cells harboring a plasmid from 
the previously described library for periplasmic expression of the 
desired Sav variant was used to inoculate a starter culture [4 ml of 
LB with kanamycin (50 mg liter−1)], which was grown overnight at 
37°C and 200 rpm. On the following day, 100 ml of LB with 
kanamycin in a 500­ml flask was inoculated to an OD600 of 0.01. 
The culture was grown at 37°C and 200 rpm until it reached an 
OD600 of 0.5. At this point, the flask was placed at room temperature 
for 20 min, and 50 M IPTG was added to induce Sav expression. 
Expression was performed at 20°C and 200 rpm overnight, and cells 
were harvested by centrifugation (3220 rcf, 4°C, 15 min). Pellets 
were stored at −20°C until purification.
Sav purification
Cell pellets were resuspended in lysis buffer [50 mM tris, 150 mM 
NaCl, and lysozyme (1 g liter−1) (pH 7.4)] so as to reach a final 
OD600 of 10. After 30 min of incubation at room temperature, cell 
suspensions were subjected to three freeze­thaw cycles. Subsequently, 
nucleic acids were digested by addition of 1 l of Benzonase (Merck 
KGaA) and 10 l of 1 M MgSO4, followed by incubation at room 
temperature for 10 min. After centrifugation, the supernatant was 
transferred to a new tube and mixed with carbonate buffer [50 mM 
ammonium bicarbonate, 500 mM NaCl (pH 11)] in a ratio of 2:3. 
Iminobiotin beads (500 l) were added, and the tubes were incubated 
at room temperature with shaking (120 rpm) for 1 hour. Afterward, 
the beads were washed twice with 15 ml of carbonate buffer and 
resuspended in 2 ml of acetate buffer [50 mM ammonium acetate 
and 500 mM NaCl (pH 4)]. After 20 min of incubation at room 
temperature with shaking, the tubes were centrifuged, and the 
supernatant was dialyzed (SnakeSkin Dialysis tubing with 3.5­kDa 
molecular weight cutoff; Thermo Fisher Scientific) against 1 liter of 
the desired buffer (table S4) for 24 hours at room temperature with 
one buffer exchange.
In vitro catalysis
In vitro reactions were performed with 2.5 M purified Sav (tetrameric; 
corresponding to 10 M biotin­binding sites) in a volume of 200 l 
in glass vials. Cofactor and substrate concentrations and buffer con­
ditions varied between reactions and are listed in table S4. Reactions 
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Data analysis
Data were analyzed using R 4.0.2 (58). For clustering and calculat­
ing amino acid effects, activity values were standardized by sub­
tracting the mean and dividing by the SD of all activity values for 
the respective reaction. Hierarchical clustering was done by calcu­
lating the Euclidian distances between all standardized activity values 
of variants harboring the respective amino acid at position 112 or 
121 (20 values per position and reaction, amounting to 200 values 
in total) and by clustering these using the hclust function (58) with 
complete linkage. The activity of all 400 mutants was further ana­
lyzed by two­way analysis of variance (ANOVA). To this end, 
positions 112 and 121 were treated as explanatory variables (with 
20 levels corresponding to the canonical amino acids). For analyzing 
the variance explained by individual factors, an interaction term was 
included, whereas it was omitted to generate a purely additive model.
Machine learning
Machine learning was implemented in R using the packages XGBoost 
(59), Keras (60), and e1071 (61). The 400 activity values for each 
reaction were randomly split into a training set comprising 320 data 
points and a test set consisting of the remaining 80 variants. The 
amino acids at positions 112 and 121 were vectorized to obtain 
different candidate descriptors using one­hot encoding, PCscores 
(62), zScales (63), VHSE (64), or physical descriptors (65). The fol­
lowing hyperparameters were optimized using grid search and 
fourfold cross­validation on the training dataset: descriptor and cost 
for SVM regression; descriptor, learning rate, maximum depth, 
subsample ratio of the training instance, subsample ratio of columns 
when constructing each tree, and number of trees for gradient 
boosting; descriptor, model architecture (two to four hidden layers, 
with number of nodes per layer between 50 and 200), batch size, 
and number of epochs for neural networks. Refer to table S5 for an 
overview of settings explored during hyperparameter tuning. The 
best combination of hyperparameters was used to train a final model 
on all 320 data points, which was then evaluated on the test set.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/4/eabe4208/DC1
View/request a protocol for this paper from Bio-protocol.
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